Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem cell and exosome therapy with ultrasound for ischemic stroke
IRCT20260524069512N1Phase 2Recruiting
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jul 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic Wharton's jelly-derived mesenchymal stem cells and mesenchymal stem cell exosomes in ischemic stroke (5 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Patient survival and viability, Adverse events and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
allogeneic Wharton's jelly-derived mesenchymal stem cellsmesenchymal stem cell exosomes
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20260524069512N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260524069512N1.